Takeda's Hemophilia A Drug: New Data and a $155 Million Patent Infringement Settlement

Takeda Pharmaceutical released data from its Phase IIIb/IV clinical trial for Adynovate at the 12th Annual Congress of the European Association of Haemophilia and Allied Disorders (EAHAD). On the same day, jurors in a Delaware federal court ordered Takeda’s Baxalta unit to pay $155.19 million to Bayer for infringing a patent for Adynovate.

Read the full article here.

0 views

Subscribe and Get Breaking News Sent to Your Inbox!

  • White Instagram Icon
  • White Facebook Icon

© 2020 HEMOTIMES | ALL RIGHTS RESERVED